Stockwinners Market Radar for December 22, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

22:59 EST Seadrill to acquire Aquadrill LLC for $958M - Seadrill Limited and Aquadrill LLC "announced that they have entered into a definitive merger agreement under which Seadrill will acquire Aquadrill in an all-stock transaction. Upon completion of the transaction Seadrill shareholders and Aquadrill unitholders will own 62% and 38%, respectively, of the outstanding common shares in the company. The transaction values Aquadrill at an implied equity value of approximately $958 million, based on Seadrill's 30-day volume-weighted average share price on the NYSE of $31.25 as of 22 December 2022. The combination creates an industry-leading offshore drilling company, with a modern and high specification fleet and a streamlined cost structure. The company will be well-placed to realize estimated annual run rate synergies of at least $70 million. The company will also be well-positioned for further growth given its stronger credit and liquidity profile, and to provide attractive cash flows."

20:25 EST Cathie Wood's ARK Investment bought 23.5K shares of Coinbase today

20:23 EST Cathie Wood's ARK Investment bought 19K shares of Teladoc today

19:23 EST Ecopetrol obtains authorization for issuance of domestic bonds in Colombia - Ecopetrol informs that the Financial Superintendence of Colombia, through Resolution 1654 of November 18, 2022, authorized the renewal of the term of the Company's Program for the Issuance and Placement of Domestic Public Debt Bonds and Commercial Paper for an additional five years, until December 22, 2027.

19:21 EST Mesoblast and Oaktree extend availability of undrawn financing - Mesoblast "announced that funds managed by Oaktree Capital Management, L.P. have extended to Mesoblast the availability of up to an additional $30.0 million of its US$90 million five year facility subject to achieving certain milestones on or before September 30, 2023."

18:48 EST Noah Holdings announces primary listing status on Hong Kong Stock Exchange - Noah Holdings announced that the company's voluntary conversion of its secondary listing status to a primary listing status on the Main Board of The Stock Exchange of Hong Kong Limited became effective December 22. The company is now a dual-primary listed company on both the Hong Kong Stock Exchange in Hong Kong and the New York Stock Exchange in the United States. The company's American Depositary Shares listed on the NYSE and the ordinary shares listed on the Hong Kong Stock Exchange are fungible, and investors can continue to choose to hold their shares in the form of ADSs traded on the NYSE or ordinary shares traded on the Hong Kong Stock Exchange.

18:31 EST OpenText says all regulatory conditions satisfied for Micro Focus deal - OpenText announced jointly with Micro Focus International that all regulatory conditions pertaining to the all-cash offer by OpenText, through its wholly-owned subsidiary, Open Text UK Holding Limited, to acquire the entire issued and to be issued share capital of Micro Focus as announced on August 25, 2022, have now been satisfied. Subject to the Court sanctioning the Scheme, which is expected to occur on January 27, 2023, the Acquisition is expected to close on January 31, 2023. "With the shareholder approval received, successful financing completed and now, all regulatory conditions satisfied, we have a clear path towards closing the Acquisition," said OpenText CEO & CTO Mark J. Barrenechea. "We are excited to welcome Micro Focus customers, partners and employees to the OpenText family and helping our customers create the digital fabrics of the future."

17:52 EST Humana wins Defense Department TRICARE East Region Contract - Humana Military has been awarded the next managed care support contract for the TRICARE East Region by the Defense Health Agency of the U.S. Department of Defense. TRICARE is the military health care program that provides benefits to military service members, retirees and their families. Under the terms of the award, Humana Military's service area would cover approximately 4.6 million beneficiaries in a region consisting of 24 states and Washington, D.C. The length of the contract is one base year with eight annual option periods, which, if all options are exercised, would result in a total contract length of nine years. This is the longest duration of a TRICARE contract since the program's inception in 1995.

17:26 EST BAE Systems awarded $119.26M Navy contract action - BAE Systems was awarded an $119.26M firm-fixed-price contract action for maintenance, modernization, and repair of USS Lassen FY23 Depot Modernization Period. The scope of this acquisition includes all labor, supervision, facilities, equipment, production, testing, and quality assurance necessary to prepare for and accomplish the CNO Availability for managing critical modernization, maintenance, and repair programs. This contract includes options, which, if exercised, would bring the cumulative value of this contract to $137.92M. Work is expected to be completed by April 2024. If all options are exercised, work will continue through April 2024. This contract was competitively procured using full and open competition via the System for Award website, with one offer received. The Naval Sea Systems Command is the contracting activity.

17:18 EST HubSpot Executive Chair sells $2.4M in common stock - In a regulatory filing, HubSpot disclosed that its Executive Chair Brian Halligan sold 8.5K shares of common stock on December 20th in a total transaction size of $2.4M.

16:34 EST Weatherford in pact with DataRob to advance AI capabilities - Weatherford International signed a multi-year agreement with DataRobot, a company in artificial intelligence, to deliver "advanced AI solutions" in its digital platforms, including the ForeSite production optimization and Centro well construction platforms. David Russell, SVP of North America Sales for DataRobot, said, "AI is already having incredible impact driving efficiency and optimization in the energy industry, and it's exciting to see the massive potential for even more transformative impact in the future. DataRobot is uniquely positioned to address challenges facing the industry today, and we're thrilled to collaborate with a leader like Weatherford to accelerate their delivery of AI-enabled solutions and gain the most value from data."

16:33 EST Procaps Group deal for Grupo Somar will not close in 2022 - The company states: "Procaps announces an update on its previously reported definitive agreement, dated as of May 16, 2022 to acquire Grupo Somar from the sellers under the SPA. As previously reported, the Company initially expected that the closing of the acquisition of Grupo Somar by the Company would occur on October 14, 2022; however, on October 13, 2022, the Company was informed by the Sellers that a condition to the Closing would purportedly not be satisfied. Specifically, the Company was informed by the Sellers that, on October 7, 2022, a court in Mexico City issued an Embargo Precautorio affecting certain shares of capital stock of Grupo Somar in connection with a pending dispute that involves an investment by a fund managed by Advent International but that is otherwise unrelated to the Sellers, Grupo Somar, the Company, or the Acquisition. The timing for resolution of the Embargo is unclear, although the Sellers have represented that they continue to work diligently towards the accomplishment of that objective. Accordingly, the Company does not expect that the Closing will occur in 2022. The Company continues to believe the strategic rationale for the Acquisition remains attractive and is discussing with the Sellers alternatives in connection with the Acquisition and its associated timing; however, the time required for resolution of the Embargo is uncertain, is not in the Company's control, and could result in further delays or prevent the Closing."

16:30 EST Loop Industries to sell Becancour site for $13.9M - Loop Industries made the following announcements: The company has entered into an agreement to sell all of its remaining property in Becancour, Quebec for $13.9M. The sale transaction is expected to close on February 24, 2023, subject to final due diligence and fulfillment of certain customary closing conditions. The company has significantly curtailed operations at its Terrebonne, Quebec production facility. This facility was constructed primarily to demonstrate that Loop's breakthrough depolymerization technology was scalable and to produce commercial quantities of virgin quality PET resin and polyester fiber for global brands. The technology is now proven at scale. The company will continue to honor its existing sales contracts, while reducing production capacity. Based on the combination of the proceeds of the land sale and the operating cost reduction initiatives at Terrebonne, the company projects to have cash on hand of approximately $33.1M at the end of the current fiscal year ending February 28, 2023 and an annual cash burn of approximately $12.5M, therefore providing close to three years of liquidity, without incurring further equity dilution to finance ongoing operating activities. The company will for now focus its commercialization strategy on its planned projects with SKGC in Asia and Europe. These joint venture projects have a lower requirement for Loop equity investment and higher return on capital, and leverage SKGC's engineering and operational infrastructure. In addition, the joint venture projects will provide Loop with an annual technology licensing fee. SKGC is committed to commercializing Loop's technology as the underpinning of its sustainable plastics strategy. Loop is working collaboratively with SKGC to put in place the financing plan for the rollout of large-scale manufacturing in Asia and Europe, including the first Asian manufacturing facility in Ulsan, South Korea, which is planned to break ground in 2023. Although the company is currently focusing on developing the planned joint venture facilities in Asia and Europe, a future facility in Quebec remains an option at the appropriate time, and possible alternative locations for such a facility are available.

16:27 EST Verizon reports 8.7% passive stake in BuzzFeed - The filing does not allow for activism.

16:22 EST Loop Industries CFO Drew Hickey to depart, Nicolas Lafond appointed interim CFO - Loop Industries announced a transition in the position of CFO. This change is announced in conjunction with other operational and strategic initiatives which are communicated in a separate press release. Effective December 30, Drew Hickey will leave the company to pursue other opportunities and Nicolas Lafond is appointed interim CFO, while the company evaluates its longer-term needs for this role as it pursues the next stage of its strategic development. Lafond currently serves as the company's director of finance.

16:18 EST Mission Produce sees Q1 pricing lower than Q4 - The company said, "The industry is expecting volumes to be higher in the fiscal 2023 first quarter versus the prior year period, primarily due to expectations for a larger Mexican harvest. The overall Mexican crop is expected to be approximately 20% higher compared to the prior harvest season, but early season volumes have lagged that figure due to primarily to low pricing. Pricing is expected to be lower on a sequential basis, but consistent with pricing experienced in the latter part of the prior quarter, which would imply a year-over-year decrease of approximately 20-25% compared to the $1.56 per pound average experienced in first quarter of fiscal 2022."

16:18 EST Cue Health selected by Minnesota Department of Health for telehealth services - Cue Health "announced that it has been selected by Minnesota Department of Health to provide a statewide COVID-19 telehealth to treatment program, powered by Cue Care(TM), at no cost to Minnesota residents."

16:16 EST Guess enters into $150M credit facility with five year term - Guess "announced that it has expanded its access to capital in North America. The Company has entered into a $150 million senior secured asset-based revolving credit facility with a term of five years. This facility amends and extends its existing $120 million North American credit facility. The amended facility has an option to further expand its total amount by up to $150 million, subject to certain conditions. Just as with its new European credit facility that was established earlier this year, the new North American credit facility will include annual interest rate and fee adjustments based on the Company's achievement of certain sustainability goals in its operating and manufacturing processes."

16:10 EST AMCON Distributing announces $5.00 per share special dividend - This cash dividend is payable on January 13, 2023 to shareholders of record as of January 3, 2023.

16:07 EST Limoneira sees FY23 fresh lemon volumes 5M-5.4M cartons - The company's food service business and industry logistics continue to experience slowdown in its supply chain as well as inflationary pressures on a global basis. The company believes it will experience improving year-over-year results in fiscal year 2023 compared to fiscal year 2022 due to its stronger position in retail food and club grocery. The company expects fresh lemon volumes to be in the range of 5.0 million to 5.4 million cartons for fiscal year 2023. Avocado volumes are expected to be in the range of 4.0 million to 5.0 million pounds for fiscal year 2023. The company now expects to receive an over 20% increase in total proceeds of $115 million from Harvest at Limoneira and the addition of LLCB II and East Area II spread out over seven fiscal years, with approximately $8 million received in fiscal year 2022.

16:06 EST Expion360 to be 'exclusive' lithium ion battery supplier for overland trailer - Expion360 as been selected as the exclusive supplier of high-energy lithium ion batteries for an overland trailer to be branded and sold by a top U.S. sports utility vehicle manufacturer. Inspired by military ruggedized surveillance trailers and developed by leaders in advanced vehicle engineering, the award-winning overland trailer sets a new benchmark for off-road performance, comfort and clean power capability. Expion360 state-of-the-art Li-ion batteries have been integrated as a key element of the trailer's onboard solar-powered storage system. Power systems equipped with Expion360 lithium batteries will be included as standard equipment on the top models. Expion360 plans to begin shipping lithium batteries to the trailer manufacturer in the first quarter of 2023. Expion360 looks forward to a long and prosperous relationship with this manufacturer. The overland trailer is expected to be available for purchase through more than 5,000 SUV dealers across North America starting early next year.

16:02 EST Bausch + Lomb amends CEO separation agreement - Bausch + Lomb and its CEO, Joseph Papa, have entered into an Amended and Restated Separation Agreement pursuant to which Papa has agreed to continue serving as CEO until at least March 4, 2023 and lasting until such date as the Board of Directors determines in its discretion or his successor is appointed, but no later than June 30, 2023. The Amended Separation Agreement also made certain changes to Papa's compensation in connection with his separation from the company.

14:50 EST COO of Clean Harbors Gerstenberg sells over $1.9M in company shares - The COO of Clean Harbors Eric Gerstenberg disclosed in a filing that he had sold 16,409 shares of company stock on December 21, at $116.02 per share, for a total transaction amount of $1,903,833.

14:10 EST Bombardier CEO concerned Canada may award sole-source contract to Boeing - Bombardier (BDRBF) CEO Eric Martel said in a statement released yesterday: "As President and CEO of Bombardier, I want to publicly share my concern that Canada, which is facing an important choice about the airborne surveillance of its vast borders, may be considering awarding a sole-source contract directly to Boeing (BA). With special mission equipment getting smaller and smaller as technology progresses, we at Bombardier firmly believe that the Global 6500 aircraft will be the right-sized solution and will respond to Canada's needs, thanks to its: Longer range offering, endurance and proven reliability; Next-generation engines and a leading aerodynamic profile that contributes to excellent operating costs and, more importantly, a lower carbon footprint. A Canadian Multi-Mission Aircraft tender, open to diverse proposals, would be an opportunity for Canada to re-think its surveillance capabilities. A Canadian-built option should, and must, be considered on equal footing with those of foreign companies who have, in the past, directly, attacked our home-grown aircraft programs. Canada has the skills, the industrial footprint and the technological capabilities to succeed in this sphere and become more than an exporter of technology. This is the ultimate opportunity for Canadians to look to the skies and proudly trust a Canadian-built aircraft to defend our borders and support our allies. On behalf of its more than 10,000 talented employees in Ontario and Quebec, Bombardier and its growing Defense team, along with its skilled partners, would be proud to put forward a made-in-Canada solution to compete in a Canadian Multi-Mission Aircraft tender, should Canada give us the opportunity to do so."

13:42 EST LiveOne moves record date to Jan. 15, 2023 for PodcastOne's special dividend - LiveOne announced that it "remains committed" to spinning-out its wholly owned subsidiary, PodcastOne, as a separate public company to be listed on a national exchange. In connection with such spin-out, LiveOne is moving the record date to Jan 15, 2023 for PodcastOne's special dividend to LiveOne's stockholders of record. In addition, LiveOne intends to explore spinning-out SlackerOne as a separate public company during its 2024 fiscal year, the company stated in a press release.

13:02 EST Baker Hughes reports U.S. rig count up 3 to 779 rigs - Baker Hughes reports that the U.S. Rig Count is up 3 from last week to 779 with oil rigs up 2 to 622, gas rigs up 1 to 155 and miscellaneous rigs unchanged at 2. The U.S. Rig Count is up 193 rigs from last year's count of 586 with oil rigs up 142, gas rigs up 49 and miscellaneous up 2. The U.S. Offshore Rig Count is unchanged at 15, flat year-over-year. The Canada Rig Count is down 103 from last week to 96, with oil rigs down 92 to 32, gas rigs down 11 to 64. The Canada Rig Count is down 37 rigs from last year's count of 133, with oil rigs down 52, gas rigs up 15.

12:33 EST Tesla: Model Y achieved highest overall weighted safety score by ANCAP - Tesla said via Twitter that the Model Y "achieved the highest overall weighted safety score of any vehicle tested this year by ANCAP." ANCAP is Australia and New Zealand's independent voice on vehicle safety. Reference Link

12:00 EST Direxion Daily Semiconductor Bull 3X Shares falls -16.0% - Direxion Daily Semiconductor Bull 3X Shares is down -16.0%, or -$1.78 to $9.36.

12:00 EST Natuzzi rises 9.5% - Natuzzi is up 9.5%, or 65c to $7.49.

12:00 EST Youdao rises 18.2% - Youdao is up 18.2%, or $1.05 to $6.83.

11:37 EST Nuwellis Inc trading halted, volatility trading pause

11:18 EST Dragonfly Energy Holdings Corp trading resumes

10:28 EST Gilead announces Sunlenca granted FDA approval in multidrug resistant HIV - Gilead Sciences announced that Sunlenca, in combination with other antiretroviral, has been granted approval by the U.S. Food and Drug Administration for the treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection. Sunlenca has a multi-stage mechanism of action distinguishable from other currently approved classes of antiviral agents and no known cross resistance exhibited in vitro to other existing drug classes, Gilead said. Sunlenca offers a new, twice-yearly treatment option for adults with HIV that is not adequately controlled by their current treatment regimen. The FDA approval for Sunlenca is supported by data from the Phase 2/3 CAPELLA trial, which evaluated lenacapavir in combination with an optimized background regimen in people with multi-drug resistant HIV-1 who are heavily treatment experienced. CAPELLA participants had undergone previous treatment with a median of nine antiretroviral medications. In this patient population with significant unmet medical need, 83% of participants randomly allocated to receive lenacapavir in addition to an optimized background regimen achieved an undetectable viral load at Week 52. Additionally, these participants achieved a mean increase in CD4 count of 82 cells/microL. These data were presented at the 29th Conference on Retroviruses and Opportunistic Infections.

10:15 EST Sight Sciences trading halted, volatility trading pause

10:00 EST Lanvin Group falls -15.5% - Lanvin Group is down -15.5%, or -85c to $4.65.

10:00 EST Amprius Technologies falls -17.9% - Amprius Technologies is down -17.9%, or -$1.60 to $7.35.

10:00 EST Direxion Daily Semiconductor Bear 3X Shares rises 9.9% - Direxion Daily Semiconductor Bear 3X Shares is up 9.9%, or $3.49 to $38.78.

09:47 EST Direxion Daily Semiconductor Bull 3X Shares falls -8.0% - Direxion Daily Semiconductor Bull 3X Shares is down -8.0%, or -89c to $10.25.

09:47 EST AMC Entertainment falls -17.9% - AMC Entertainment is down -17.9%, or -95c to $4.35.

09:47 EST Direxion Daily Semiconductor Bear 3X Shares rises 8.2% - Direxion Daily Semiconductor Bear 3X Shares is up 8.2%, or $2.89 to $38.18.

09:45 EST CarMax CFO says lowering headcount through attrition - Asked on the company's earnings call why CarMax is not choosing to reduce expenses or headcount more quickly across other parts of the enterprise, CFO Enrique Mayor-Mora replied in part: "Yes. And what I'd say there is that we did. And so as sales got more challenged third quarter, we went deeper into the staffing levels in the field. And so it's still through attrition, so it is take a little bit longer. But at the same time, we did lower our staffing targets to reflect the current sales environment... In addition to just slowing down some of the capacity initiatives that we have out there in terms of growing our capacity with lower volume, we're just slowing down some of those investments." CEO William Nash then added: "And Daniel, the only thing I would add there is, look, we're -- and our culture is one that's a people-first mindset. Our people are the reason for our success. And that's the reason we've chosen to allow attrition to get us to where we need to be. We'll obviously continue to monitor the situation, but we're very comfortable with allowing attrition to get us to where we need to be."

09:41 EST CarMax CEO expects average selling prices to 'continue to fall' - Asked if he is "still confident" that the company's GPU targets are achievable in a scenario where hypothetically average selling prices, or ASPs, fall another 5% to 10% over the next couple of quarters, CarMax CEO William Nash replied: "Yes. Look, I think we feel very comfortable where we're running the retail GPUs. We'll continue to monitor the test. But look, I expect ASPs to continue to fall, which I think overall for the industry is a good thing to help drive some gap between new and late-model use. So we feel comfortable with where our GPUs are and we'll continue to test."

09:31 EST Harbor Custom Development appoints Karen Bryant as lead independent director - Harbor Custom Development announced the Board of Directors have appointed Karen Bryant, former Seattle Storm CEO, as the board's lead independent director, effective immediately.

09:29 EST NFL announces multi-year agreement with Google's YouTube for NFL Sunday Ticket - The National Football League announced a multi-year agreement with Google granting YouTube TV and YouTube Primetime Channels the right to exclusively distribute NFL Sunday Ticket to consumers in the United States starting with the 2023 NFL season. "This strategic partnership will provide fans greater access to NFL Sunday Ticket while tapping into the best of YouTube's technology and product innovation... Starting next season, NFL Sunday Ticket will be available on two of YouTube's growing subscription businesses as an add-on package on YouTube TV and standalone a-la-carte on YouTube Primetime Channels. Consisting of all out-of-market Sunday regular-season NFL games (based on viewer's location) broadcast on FOX and CBS, NFL Sunday Ticket allows fans in the United States the ability to follow all their favorite teams and players no matter where they live. Updated NFL Sunday Ticket product features and functionality will be announced ahead of the 2023 NFL season. NFL Sunday Ticket launched in 1994 and has been distributed on DirecTV's satellite service since its inception. The NFL and YouTube will work together to determine additional ways to support distribution of NFL Sunday Ticket in commercial establishments such as bars and restaurants," the league stated. "We're excited to bring NFL Sunday Ticket to YouTube TV and YouTube Primetime Channels and usher in a new era of how fans across the United States watch and follow the NFL. For a number of years we have been focused on increased digital distribution of our games and this partnership is yet another example of us looking towards the future and building the next generation of NFL fans," NFL Commissioner Roger Goodell said. Susan Wojcicki, CEO of YouTube, added: "Through this expanded partnership with the NFL, viewers will now also be able to experience the game they love in compelling and innovative ways through YouTube TV or YouTube Primetime Channels. We're excited to continue our work with the NFL to make YouTube a great place for sports lovers everywhere." Reference Link

09:17 EST Medipharm Labs to acquire Vivo Cannabis in all-equity business combination - MediPharm Labs (MEDIF) and VIVO Cannabis Inc. (VVCIF) announced that MediPharm and VIVO have entered into a definitive arrangement agreement whereby MediPharm has agreed to acquire VIVO in an all-equity business combination transaction. The Transaction is expected to combine two highly complementary businesses, creating a unique and market differentiating international medical cannabis leader. Upon the completion of the Transaction, existing MediPharm shareholders are expected to own between 65% and 79% of the combined company resulting from the Transaction and VIVO shareholders are expected to own between 35% and 21% of the Combined Company.Under the terms of the Arrangement Agreement, holders of common shares of VIVO will receive between 0.2110 and 0.4267 common shares of MediPharm for each VIVO Share held, subject to adjustment. The Exchange Ratio at closing will be determined by the amount of interim working capital of VIVO taking into account any funds advanced by MediPharm to VIVO up to a maximum of $3.75M, by way of a promissory note. The Interim Working Capital will allow VIVO to continue operations in the ordinary course throughout the proposed closing period. Holders of VIVO Shares will be entitled to receive such number of common shares of the Combined Company as is equivalent to 35% of the issued and outstanding common shares of the Combined Company, which may be reduced depending on the Interim Working Capital of VIVO prior to closing, to a minimum of 21% of the issued and outstanding common shares of the Combined Company. Using forecasts derived collaboratively by both management teams, along with revenue and cost synergy estimates, the pro-forma Combined Company aims to find positive EBITDA synergies to the magnitude of between $7M to $9M on an annualized basis, and could reach positive EBITDA and cash flow in the first half of 2024. The Transaction is to be carried out by way of a court-approved plan of arrangement under the Canada Business Corporations Act. The Transaction will require the approval of: two-thirds of the votes cast by shareholders of VIVO, and, if required,a simple majority of the votes cast by minority VIVO shareholders in accordance with Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions, at a special meeting of VIVO shareholders expected to take place in the first quarter of 2023; and a majority of the votes cast by shareholders of MediPharm at a special meeting of MediPharm shareholders expected to take place in the first quarter of 2023. MediPharm has entered into voting and support agreements with each of its directors and officers and each person that, to the knowledge of MediPharm, holds at least 5% of the MediPharm Shares, pursuant to which these parties have agreed, subject to certain rights of withdrawal, to vote in favour of the Arrangement and not to dispose of their MediPharm Shares. VIVO has entered into voting and support agreements with each of its directors and officers and each person that, to the knowledge of VIVO, holds at least 5% of the VIVO Shares, pursuant to which these parties have agreed, subject to certain rights of withdrawal, to vote in favour of the Arrangement and not to dispose of their VIVO Shares. Completion of the Transaction is subject to court and regulatory approvals, including the approval of the Toronto Stock Exchange, which are currently expected to be received during the first half of 2023. The transaction is expected to close during the first half of 2023. The Arrangement Agreement contains certain customary provisions, including covenants in respect of non-solicitation of alternative acquisition proposals for VIVO and a termination fee of $1M payable to either party in certain circumstances.

09:13 EST Westrock Coffee down 25% after filing to sell 19.9M shares issuable by warrants - Shares of Westrock Coffee are down 25% at $9.99 in pre-market trading after the company's 424B filing, stating: "This prospectus relates to the issuance by us of up to 19,900,000 shares of common stock, par value $0.01 per share, of Westrock Coffee Company, a Delaware corporation that are issuable by us upon the exercise of the outstanding warrants, which were previously registered, including Warrants that are listed on the Nasdaq Stock Market. This prospectus also relates to the potential offer and sale from time to time by the securityholders named in this prospectus or certain transferees of up to 95,937,824 Common Shares, consisting of (i) 20,240,000 Common Shares issued in the PIPE Financing, (ii) up to 7,400,000 Common Shares issuable upon exercise of the Warrants held by Riverview Sponsor Partners, LLC, (iii) 40,400,872 Common Shares held by our pre-Business Combination equityholders, (iv) 4,309,000 Common Shares held by entities affiliated with R. Brad Martin and (v) up to 23,587,952 Common Shares issuable upon the conversion of the outstanding shares of Series A convertible preferred stock, par value $0.01 per share, of Westrock."

09:06 EST Stingray Group launches TV channels on Amazon Freevee, Samsung TV Plus - Stingray (STGYF) announced the launch of free ad-supported TV channels Stingray Music, Stingray Naturescape and Stingray CMusic with two major OTT providers: Freevee (AMZN) and Samsung TV Plus (SSNLF). These distribution agreements grow Stingray's audience over new platforms in new territories and add millions of potential viewers.

09:03 EST SG Blocks changes name to Safe & Green - Safe & Green is the new name of SG Blocks. The new name, logo and branding elements were introduced in an effort to better reflect Safe & Green Holdings position as a developer, designer, and fabricator of modular structures. The Company's common stock will continue to trade on the Nasdaq Stock Market under its current ticker symbol (SGBX).

08:51 EST CarMax pauses share repurchases - "Given third quarter performance and continued market uncertainties, we are taking a conservative approach to our capital structure. Accordingly, we have paused our share repurchases. During the third quarter of fiscal 2023, we repurchased 30,000 shares of common stock for $2.6 million pursuant to our share repurchase program before pausing additional purchases. As of November 30, 2022, we had $2.45 billion remaining available for repurchase under the outstanding authorization. We remain committed to returning capital back to shareholders over time and may resume share repurchases in the future at any time depending upon market conditions and our capital needs, among other factors."

08:48 EST Akebia receives interim response from FDA on appeal of vadadustat submission - Akebia Therapeutics received an interim response from the FDA to its Formal Dispute Resolution Request regarding the Complete Response Letter received in March 2022 for vadadustat, which had been submitted to the FDA as a treatment for anemia due to chronic kidney disease in adult patients. Akebia met with the FDA in November to discuss its appeal and subsequently received a request for additional clarifying information from the Office of New Drugs, Center for Drug Evaluation and Research, which is deciding the appeal. Akebia remains engaged with the FDA and expects to submit the requested information to the FDA in January 2023. Based on FDA guidance, Akebia expects to receive a response to its appeal 30 days from the date Akebia submits the requested information.

08:43 EST Cenntro's Logistar 400 receives EPA's certificate of conformity - Cenntro Electric announced that its all-electric Class 4 Logistar 400 model received a U.S. Environmental Protection Agency EPA Certificate of Conformity. A Certificate of Conformity was issued by the EPA to Cenntro, the vehicle manufacturer, to officially confirm that the LS400 conforms to all EPA regulations and emission standards. The LS400 previously completed the EPA range test in October.

08:40 EST American Resources' ReElement completes preliminary investment in AML - American Resources Corporation announced that it has executed its second rare earth oxide offtake agreement with Advanced Magnet Lab to provide AML high-purity raw rare earth elemental feedstock for their advanced, domestic magnet production. Concurrently with the offtake agreement, the Company has completed an initial strategic investment into AML to further advance the technology and commercialization. American Resources has led the round of investment into AML alongside a select number of strategic investors and insiders, and the investment is in the form of a promissory note that has the ability to convert into shares of common stock of AML at a fixed valuation. AML has developed PM-Wire, a unique technology for the design, manufacture and optimized performance of permanent magnets and their end-use applications. Magnets are at the heart of the products and applications essential to modern society. It is the magnets which enable electricity, manufacturing, processing of goods, movement of water, tools for construction and transportation. AML's technology provides significant value propositions for electrical machines, motors, and generators - all driven by magnets. Combined with the offtake agreement between AML and ReElement Technologies, American Resources Corporation, the parent company of ReElement Technologies, concurrently has completed an initial investment into AML though a convertible debt structure that converts into equity of AML. This investment allows American Resources and AML to each participate in the anticipated growth of their respective businesses and technologies.

08:37 EST Poet Technologies announces intention to amend warrant terms - POET Technologies intends to amend the terms of 1,764,720 common share purchase warrants of the Corporation that were issued pursuant to a private placement that closed on February 11, 2021. After giving effect to the Consolidation, the Warrants currently have an exercise price of C$11.50 per common share and will expire on February 11, 2023. The purpose of the proposed amendments is to reduce the exercise price of the Warrants from C$11.50 to C$4.25 per Common Share, extend the expiry date of the Warrants from February 11, 2023 to May 11, 2023, and amend the Acceleration Clause to comply with the requirements of the TSX Venture Exchange. Following the closing of the Private Placement in 2021, the Corporation completed a consolidation of its issued and outstanding Common Shares on the basis of 1 post-consolidation common share for every 10 pre-consolidation common shares. Accordingly, the number of outstanding Warrants were consolidated on the basis of 1 post-Consolidation Warrant for every 10 pre-Consolidation Warrants and, in accordance with the terms of the warrant indenture, the exercise price of the Warrants was adjusted such that each post-Consolidation Warrant entitles the holder thereof to purchase one Common Share at a price of C$11.50 per Common Share during the unexpired term of the Warrants. Warrantholder Approval In accordance with the terms of the warrant indenture under which the Warrants were issued, the Amendments must be approved by the holders of not less than 66 2/3 percent of the outstanding Warrants. Therefore, in order to give effect to the Amendments, the Corporation will be promptly seeking the written consent of the holders of Warrants to such Amendments. Upon the Amendments becoming effective, each Warrant will be exercisable until 5:00 p.m. on May 11, 2023 at an exercise price of C$4.25 per Common Share. In addition, the Warrants will be subject to an amended clause whereby, if for any 10 consecutive trading days during the unexpired term of the Warrants, the closing price of the Common Shares on the Exchange is equal to or greater than C$4.89, the expiry date will be accelerated to 30 calendar days. The Corporation will announce any such accelerated expiry date of the Warrants by news release. All other terms and conditions of the Warrants remain the same. The amended warrant terms remain subject to the final acceptance of the Exchange.

08:34 EST E-Home Household Service to set up Haixia Home Management College - E-Home Household Service has made substantial progress in the Haixia Home Management College which has been prepared for more than three years, i.e. reached agreement with special investors to invest in the college, and at the same time obtained the support from the government of Pingtan Comprehensive Experimental Zone to be officially settled in Pingtan. E-Home with dedicated investors is expected to invest RMB600M, and the first phase is expected to invest RMB300M to set up a higher education college in Pingtan, introducing an international advanced education system to achieve a three-year system, with an average annual full-time school size of 10,000 people and academic upgrading practice. The non-academic education vocational training is expected to be 30,000-50,000 people. Haixia Home Management College will have the dual function of higher specialized vocational education and home management service industry.

08:34 EST WaveDancer signs multi-year contract with commercial customer - WaveDancer announced that the Company signed another customer for their Maverix Blockchain platform. The multi-year engagement is expected to exceed $500,000 in new subscription revenue. "We are thrilled to be able to assist another customer with their supply chain management needs. Since the completion of our commercial platform this fall, our Sales & Marketing efforts have been steadily gaining momentum," said Randy Boone, WaveDancer's Chief Revenue Officer. "This customer came to us needing a unique capability that matched the complexity of its operating environment. They chose Maverix because our easy-to-use software combines enterprise-level traceability and visibility with the security, immutability and transparency of blockchain - something you just can't get out of your traditional supply chain ERPs," Boone added. "Increasing the amount of quality data throughout the supply chain and then being able to confidently share it is critical to solving some of the supply chain challenges we see today."

08:32 EST Minim launches live shopping experience with HSN - Minim announces its debut into live shopping with HSN. The company's first live shopping event will offer HSN viewers an engaging platform to purchase products from Motorola's home networking portfolio. Hosted across HSN's streaming platforms, Minim's premiere segment will show viewers how to simplify and secure their home networks using the Motorola Q11 WiFi 6 Mesh Router System and motosync mobile app. "The company's recent expansions with leading e-commerce companies have revealed how consumers are embracing our products," said Cristina Martinho, Vice President of Performance Marketing at Minim. "HSN's engaging platform is a great way for Minim to tell their brand story and forge deeper connections with our audience."

08:31 EST ReShape Lifesciences announces 1-for-50 reverse stock split - ReShape Lifesciences announced that its Board of Directors has declared a 1-for-50 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on December 23, 2022. At that time, each 50 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. As a result of the reverse stock split, proportional adjustments will be made to the number of shares of common stock issuable upon exercise or conversion, and the per share exercise or conversion price of the company's outstanding warrants, stock options and convertible preferred stock, in each case in accordance with their terms. In connection with the reverse stock split, the company also increased the number of shares of common stock that it is authorized to issue under its certificate of incorporation to 300 million shares. The number of authorized shares of common stock and preferred stock under the company's certificate of incorporation will not be reduced in connection with the reverse stock split.

08:28 EST Polished announces results of internal investigation, to restate Q1 results - Polished made several announcements. The company's board of directors has completed its assessment of the results of the Audit Committee's previously disclosed internal investigation. The investigation, which was supported by independent legal counsel and advisors, produced the following key findings pertaining to the company's business operations under former management during the 2021-2022 period: The company was charged by its former CEO approximately $800,000 for expenses unrelated to the company and its operations. The company appears to not have had in place all the necessary documentation for all of its employees and, in turn, may have failed to comply with certain legal requirements. As elaborated on below, the company has subsequently put in place enhanced controls to remedy any labor issues and believes it is now in full compliance with legal requirements. The company's controls, software and procedures for managing and tracking inventory, including damaged inventory, were insufficient. As elaborated on below, the company has subsequently put in place enhanced controls to remedy such issues. At the board's direction, the company's new management has undertaken its own review of prior management's practices and representations. Based on a preliminary review and presently available information, the company does not expect any material restatement of its fiscal year 2021 financial results. The company does, however, expect to restate the first quarter of fiscal year 2022, reflecting a reduction in revenue of $6M to $8M and a related reduction in cost of goods sold of $5M to $7M. The likely result for the quarter is a decline in gross margin and a reduction in income from operations of $1M to $2M. Earlier this week, Polished received a resignation letter from its auditor. As a result, the company has been engaging with qualified replacements and is in advanced discussions with a new potential auditor. The company expects that its new auditor will re-audit fiscal year 2021 while also reviewing financials for the second quarter of fiscal year 2021, the third quarter of fiscal year 2021 and the first quarter of fiscal year 2022. The company plans to work with its new auditor to prepare and file all delayed and restated financial statements as soon as reasonably practicable. In terms of outlook, the Company no longer expects to hit the top-line and bottom-line guidance set forth by former management in prior statements. In addition to challenges associated with this year's management change and internal investigation, the company has been impacted by the same economic headwinds and margin pressures facing other consumer discretionary companies. In terms of remedial actions pertaining to the internal investigation, the board has reached an agreement with its former CEO to, among other things, be reimbursed for substantially all of the non-company related expenses that were charged to the company and the costs pertaining to the Audit Committee's investigation.

08:18 EST SOBR Safe sgins five additional distributors - SOBR Safe announced that it has signed five additional distributors, bringing its total representation to nine distributors and 29 U.S. sales professionals. These distributors have sold alcohol detection products to a combined 525 established customers, and each distributor has demonstrated their commitment to SOBRsafe through the purchase of multiple SOBRcheck devices. All nine distributors are fully trained, certified and are actively selling the technology to a network comprised of approximately 52,000 potential users.

08:16 EST Cerberus Cyber Sentinel to become CISO Global - Cerberus Cyber Sentinel announced plans for a corporate rebrand and launch. At the heart of the rebranding is a change of the company name to CISO Global, and an update to its corporate logo. The new brand identity marks another major milestone in the evolution of Cerberus Sentinel, embodies the enthusiasm of its employees, and is indicative of the company's movement forward. "The distributed nature of cybersecurity requires global capabilities to properly address the demands and complexities of today's business environment," said Ashley Devoto, president and CISO of CISO Global. "The company's M&A growth strategy has been one that takes into account the cybersecurity market's $2 trillion opportunity as well as the cyber talent shortfall. That, combined with growing cybersecurity compliance complexities and requirements, including those by the U.S. Securities and Exchange Commission and the U.S. Department of Defense Cybersecurity Maturity Model Certification, means that businesses are facing mounting pressure often beyond their capacity to manage internally."

08:14 EST Republic First Bancorp appoints Thomas Geisel CEO - Republic First Bancorp announced several leadership changes. Thomas Geisel has been appointed Chief Executive Officer and President, and as a member of the Board of Directors, effective immediately. Mr. Geisel has a diverse financial services background, including leadership experience growing regional banks for more than twenty years - most recently as President, Corporate Banking, at Webster Bank . Additionally, Michael W. Harrington has been appointed Chief Financial Officer, effective immediately. Mr. Harrington's background includes extensive experience in community banking and financial services - most recently as Chief Financial Officer of Bryn Mawr Trust.

08:13 EST Outlook Therapeutics announces validation of MAA by EMA for ONS-5010 - Outlook Therapeutics announced the validation of its Marketing Authorization Application, MAA, by the European Medicines Agency, EMA, for ONS-5010 / LYTENAVA, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration. The formal review process of the MAA by the EMA's Committee for Medicinal Products for Human Use, CHMP, is now set to begin with an estimated decision date expected in early 2024. "The validation of our MAA by the EMA is another exciting moment for our team in 2022 and takes us one step closer to offering clinicians and their patients the first and only on-label, ophthalmic bevacizumab to treat wet AMD," said Russell Trenary, President and CEO of Outlook Therapeutics. "In addition to the recent acceptance of our BLA by the U.S. FDA and our continued progress toward commercial launch, pending approval, we believe ONS-5010 is well-positioned to provide a preferred treatment option for the retina community and enhance the standard of care in the anti-VEGF space." The MAA submission is supported by results from Outlook Therapeutics' wet AMD clinical program for ONS-5010, which consists of three completed registration clinical trials - NORSE ONE, NORSE TWO and NORSE THREE. The regulatory exclusivity for ONS-5010 could potentially be increased by an additional two years if Outlook Therapeutics pursues approvals for additional indications. Outlook Therapeutics is assessing both direct commercialization and partnering in Europe on a country-by-country basis

08:12 EST ReWalk Robotics announces extension of share repurchase program - ReWalk Robotics announced that its Board of Directors has approved an extension of the current program to repurchase the Company's Ordinary Shares, par value NIS 0.25 per share, with such extension to be in the aggregate amount of up to $5.8 million. The Company's ongoing $8.0 million repurchase program was previously approved by the Board and an Israeli court for a six month period ending on January 20, 2023. The Board's approval of the $5.8 million repurchase program extension is intended to facilitate purchases of up to an aggregate of $8.0 million of its Ordinary Shares over the life of the repurchase program, as extended. "We believe our stock is significantly undervalued and this filing to extend our repurchase program reflects our confidence in the long-term potential of ReWalk," stated Jeff Dykan, Chairman of the Board. "The Board approved the program as part of its ongoing consideration of alternative methods to take advantage of the Company's strong cash position and based on the input of our shareholders. We believe the program represents a prudent use of the Company's capital and signals the Board's priority to maximize shareholder value."

08:11 EST Bit Origin mines 8.59 bitcoin in November - Bit Origin provided its monthly production and operation update for November 2022. "Our production in November 2022 was negatively affected by the strong volatility of the bitcoin price and high energy costs. As a result, we temporarily scaled down our operations to cut down costs. We have also reached a strategic agreement with Your Choice 4 CA, Inc., the host in our Indiana site to share electricity expense, which is expected to significantly increase our profit margin. We continue adjusting our short-term strategy to optimize our operating efficiency in the current dynamic market conditions." said Lucas Wang, Chairman and Chief Executive Officer of the Company. Bit Origin started bitcoin mining in mining sites in Georgia and Indiana in May and June 2022, respectively. As of November 30, 2022, the total mining hash rate remains at 308 PH/s with 3,190 miners installed. The Company mined 8.59 Bitcoins and achieved a revenue of $166,911 in November 2022, representing a decrease of 65% and 65%, respectively, compared to the previous month.

08:10 EST Sandoz Canada supports Ontario policy change on biosimilars - Sandoz welcomes the Ontario Government introduction of biosimilars switch policy to expand the use of biosimilars available on the market and generate significant cost savings to the province healthcare system. Biosimilars are not new. There is extensive use of biosimilars in Canada including 50 biosimilars already approved for use in the Canadian market to date. Health Canada is clear that physician-supervised switching is a safe and efficacious practice, and the safety and efficacy of switching patients to biosimilars is also well established internationally and supported by numerous studies. "Biosimilar switch policies are an important step towards increasing patient access to quality and potentially life-enhancing biosimilar medicines they need while realizing significant health system cost savings. We support the promotion of wider adoption of biosimilars to reinvest savings into healthcare resources and enable more patients to experience the benefits of biologic treatment," said Michel Robidoux, President and General Manager at Sandoz Canada and Chair of Biosimilars Canada.

08:10 EST Westwater Resources determines Idaho Strategic proposal not in best interest - Westwater Resources (WWR) announced that the company had received an unsolicited proposal from Idaho Strategic Resources (IDR) on December 15. IDR publicly disclosed its proposal on December 22. The company said, "Westwater is focused on developing battery-grade natural graphite products through its Kellyton advanced graphite materials processing plant (the "Kellyton Plant") that is under construction in east-central Alabama. Westwater also holds the mineral rights to mine graphite from two properties in Alabama, one in Coosa County and the other in Chilton County, and efforts have begun to permit the graphite deposit in Coosa County. The Company has estimated the cost to construct and commission Phase I of the Kellyton Plant to be approximately $202 million, of which approximately $50 million has been incurred through the end of the third quarter of Fiscal Year 2022. With approximately $100 million in cash on its balance sheet as of September 30, 2022, the Company is considering various forms of financing to fund the remaining construction of the Kellyton Plant. IDR first contacted Westwater in early December 2022 regarding a potential transaction. Although Westwater offered to hold an introductory call with IDR in late December 2022, IDR choose, instead, to submit an unsolicited proposal to Westwater on December 15, 2022, prior to having any direct dialogue with Westwater. The proposal lacked important information regarding the ability of IDR to finance its existing business plans. Furthermore, the proposal did not include any information regarding the ability of a combined company to advance the construction of the Kellyton Plant or Westwater's business plans. After considering the proposal with the Westwater Board and management team, on December 19, 2022, the Board and management determined that, at this time, it was not in the best interests of the Company to pursue the proposal further. IDR's financial statements as of September 30, 2022 revealed that IDR has negative operating cash flow for first nine months of 2022 and had cash on hand, net of accounts payables, accrued payroll related liabilities, and current note payable obligations of less than $1 million, which indicates that IDR: lacks sufficient financial resources to advance its business, and would likely siphon resources from Westwater to fund unproven exploration projects; lacks the resources to complete Phase I construction of the Kellyton Plant; and cannot even cover the transaction costs associated with its own proposal. Further, Westwater understands that IDR operates a single gold mine and mill, and that it is exploring properties for thorium and rare earth element mining as well as additional gold mining - but it does not own, and it does not mine any graphite properties or have any technical expertise in producing advanced graphite products. Taken as a whole, Westwater believes the proposal advanced by IDR: Lacks technical or strategic synergies as it appears to be premised on discarding the Kellyton Plant which has been under construction for approximately one year and is expected to position the Company at the forefront of the domestic energy transition; Is an opportunistic attempt by IDR to utilize cash from Westwater's balance sheet that is based on a false assumption that the Westwater's cash balance is available to advanced IDR's business plan. However, Westwater's cash balance is already substantially committed to the construction of Phase I of the Kellyton Plant; and As previously stated by Westwater, the Company is working to secure the additional funding needed to complete Phase I construction and does not believe the proposal unlocks additional opportunities to complete the funding of Phase I of the Kellyton Plant. Rather, this opportunistic proposal represents an unnecessary distraction and cost to the Company. For the reasons outlined above, Westwater responded to IDR that, at this time, it was not in the best interests of the Company to pursue the proposal further at this time."

08:08 EST Uxin completes upgrade on Xi'an Inspection and Reconditioning Center - Uxin completed the relocation and upgrade of its Xi'an Inspection and Reconditioning Centeras well as its used car superstore. The upgraded IRC and superstore reopened for business as the largest fully self-owned used car marketplace in Northwest China with a showroom capacity of up to 3,000 vehicles to meet the used car consumption demand in the city of Xi'an and its surrounding areas.

08:07 EST COMSovereign Holding sells Sky Sapience drone subsidiary for $1.8M - COMSovereign Holding announced an agreement to sell its Israel-based, Sky Sapience tethered drone unit to Titan Innovations for total cash consideration of $1.8M. Titan Innovations, based in Israel, is a developer of specialized, fully integrated unmanned systems and solutions designed for civilian and military applications. Under terms of the transaction, Titan will acquire Sky Sapience which includes all business assets and intellectual property.

08:07 EST INmune Bio , VCU, Barrow Neurological receive DoD funding - INmune Bio, a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease in concert with Virgina Commonwealth University, VCU, and Barrow Neurological Institute have received a grant from the Department of Defense, DoD. The grant is titled: Novel solTNF inhibitor improves outcomes in a mouse model of TBI-induced AD. The funding covers a collaboration that studies the impact of traumatic brain injury in the development of Alzheimer's disease related pathology. These DoD funded studies are a collaboration between Dr. Kirsty Dixon, Associate Professor of Surgery and director of Surgery's Neurotrauma Repair Laboratory at Virginia Commonwealth University, and Dr. Elliott Mufson, Professor of Neurobiology and the director of the Alzheimer's disease research laboratory at Barrow Neurological Institute and INmune Bio. "This is a great example of collaboration for innovation," said RJ Tesi MD, CEO of INmune. "Two stellar academic institutions combine with industry and government to answer an important medical question."

08:06 EST Rigel Pharmaceuticals says REZLIDHIA now available in U.S. by prescription - Rigel Pharmaceuticals announced that REZLIDHIA capsules are available in the U.S. by prescription for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test. REZLIDHIA is an oral, small molecule, inhibitor of mutated IDH1 designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells. REZLIDHIA was approved by the U.S. FDA on December 1, 2022.

08:05 EST Acasti Pharma announces preliminary resulst in study of GTX-101 - Acasti Pharma announced that preliminary topline results for its single-dose, pharmacokinetic bridging study to evaluate the relative bioavailability of GTX-101 compared to the reference listed drug in the U.S., bupivacaine subcutaneous injectable, met all primary outcome measures for the study. The final clinical study report is anticipated to be received by the Company in the first half of 2023. This PK study was the next step in the proposed 505(b)(2) regulatory pathway for GTX-101 and provides important information on the dose and dosing frequency in humans for future planned clinical studies. Primary outcome measures and their definitions include: The median time to reach the maximum concentration of bupivacaine in plasm following GTX-101 single-dose topical applications of 50, 100 and 200 mg ranged between 18 to 24 hours depending on dose, while the median Tmax following the subcutaneous injection of 10 mg of bupivacaine was only 23 minutes. This finding suggests that the bupivacaine delivered by GTX-101 remains in the skin for a long period of time, potentially inducing prolonged analgesic effect in the sprayed area. The exposure to bupivacaine based on Cmax and AUC following GTX-101 topical application as a single-dose of 50, 100 and 200 mg, increased with increasing dose. This was predictable and expected. The systemic exposure to bupivacaine following a 200mg dose of GTX-101 was: Approximately 29-fold less than a single subcutaneous dose of 10mg of bupivacaine based on Cmax and, Approximately 6-fold less than a single subcutaneous dose of 10mg of bupivacaine based on AUC. These results are predicted to correspond to an increased safety margin for GTX-101 with regards to toxicity risk. The mean half-life following GTX-101 single-dose topical application of 50, 100 and 200 mg ranged between 24 to 37 hours depending on dose, suggesting a slow elimination and potentially long duration of effect, while the mean Thalf following the subcutaneous injection of 10 mg of bupivacaine was only 8 hours. Adverse events judged as related to the study drug by the investigator were: Following GTX-101 topical application: headache and numbness at the sprayed area, and Following bupivacaine subcutaneous injection: dizzines and nausea.

08:05 EST DarioHealth announces new partnership with ECES - DarioHealth announced a new partnership with ECES, an international wellness company, to deploy Dario Move throughout Greece and Cyprus as part of a planned government sponsored initiative. The program will launch in early 2023 with a mandate to screen a minimum of 50,000 citizens in support of improving musculoskeletal health of the Greek and Cyprus populations.

08:03 EST Nikola receives CARB ZEP Executive Order - Nikola announced that it has received a California Air Resources Board Zero Emission Powertrain Executive Order that is a requirement for Nikola's Tre hydrogen fuel cell electric vehicle to be eligible for CARB's Hybrid and Zero Emission Truck and Bus Voucher Incentive Project program. Following receipt of this Executive Order, Nikola has submitted an application for eligibility of the Nikola Tre FCEV as an authorized vehicle under the HVIP program for a base incentive amount valued at $240,000 per FCEV truck. Upon final HVIP approval, purchasers of the Nikola Tre FCEV in 2023 will be able to qualify for a base incentive valued at $240,000 per truck; $270,000 per truck for drayage fleets; or up to $288,000 per truck for fleets with (i) 10 trucks or less, (ii) performing drayage operations, and (iii) located within a disadvantaged community area. Eligible non-drayage fleets may secure up to 30 HVIP vouchers and drayage fleets may secure up to 50 vouchers. In addition to the funding provided by HVIP, purchasers of Nikola's Tre battery-electric vehicle and FCEVs will also qualify for an additional $40,000 in clean commercial vehicle tax credits in 2023 from the federal government due to the passage of the Inflation Reduction Act.

08:02 EST Mullen Automotive announces I-GO arrived in Europe - Mullen Automotive announces that the I-GO Commercial Urban Delivery EV has arrived in Europe with sample vehicles now en route to Newgate Motor Group in Ireland with expected delivery in early January 2023. The sample vehicles were initially expected to arrive at Newgate on Dec. 20, 2022, but delivery was delayed due to COVID related shutdown issues in China. The I-GO is Mullen's recently announced urban commercial delivery vehicle, designed to bridge the gap between the growing demand for quick deliveries and space constraints in dense cities throughout Europe. "The initial I-GO samples have arrived in Europe and are now on their way to Newgate in Ireland," said David Michery," CEO and chairman of Mullen Automotive. "We are excited for sales and service to get up and running with Newgate. Once established, we will look further into other opportunities for the European Market. The I-GO is a great alternative vehicle for delivery in dense metro European cities. The small size is perfect for maneuverability on tight euro streets and the zero emissions and lower cost of ownership is a great combination for our potential commercial customers."

07:57 EST Otonomy receives Nasdaq notification of trading suspension - Otonomy announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market indicating that the company's shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022. Following such suspension, the company's shares will be traded on the OTC Pink Market. As previously reported, on November 14, 2022, Otonomy received a notice from Nasdaq indicating that the Listing Qualifications Staff had determined to delist the company's securities unless the company timely requested a hearing before the Nasdaq Hearings Panel. The Staff's determination was due to the company's securities having a closing bid price of less than $0.10 per share for the preceding ten consecutive trading days. On December 1, 2022, the Company submitted a request for a hearing and delisting was stayed pending the company's hearing with the Panel scheduled for December 22, 2022. Following Otonomy's announcement of its Plan of Dissolution on December 19, 2022, the company had further discussions with Nasdaq personnel and determined that its plan would not support regaining compliance to maintain the listing of its securities on Nasdaq. On December 21, 2022, the company notified Nasdaq of its intention to withdraw from the Nasdaq hearing process. Based on Nasdaq's procedures, once the withdrawal from the hearing process has been made, delisting of the stock occurs two business days later. Accordingly, Nasdaq will suspend trading of Otonomy's shares effective at the open of business on December 23, 2022. Following such suspension, Otonomy's shares will be traded on the OTC Pink Market.

07:48 EST Small Pharma completes SPL026 Phase IIa trial, receives European patent - Small Pharma announces that the last patient has completed its final visit in the Phase IIa clinical trial of SPL026, intravenous N,N-dimethyltryptamine, with supportive therapy, for the treatment of Major Depressive Disorder. The proof-of-concept Phase IIa clinical trial investigates intravenous SPL026 with supportive therapy, in MDD patients. This two-staged study included a blinded, randomized, placebo-controlled phase, where the primary endpoint was to assess the efficacy of a single dose of SPL026 versus placebo. In addition, all participants were rolled into an open-label phase of the study where they each received an active dose of SPL026 and were subsequently followed-up for 12 weeks. This trial design enables the assessment of secondary endpoints including the efficacy, safety, and tolerability of one versus two doses of SPL026. Efficacy is being assessed using the Montgomery-Asberg Depression Rating scale to measure any potential change in patients' depression. On December 21, 2022, the Company was granted patent no. 3 873 883 by the European Patent Office. The European patent protects a manufacturing process for the preparation of synthetic DMT, DMT-related compounds and deuterated DMT analogs. The claimed novel manufacturing process produces an efficient, Good Manufacturing Practice compatible formula, that is inexpensive to manufacture and scalable for commercial purposes. The European patent covers the preparation of the Company's pipeline candidates SPL026 and SPL028. This patent marks the first grant within the Company's synthetic route patent family, with patent applications pending in multiple additional jurisdictions, including the United States and Canada.

07:38 EST Lordstown Motors announces Lordstown Endurance on site at CES - Lordstown Motors announced that the Lordstown Endurance full-size battery-electric pickup truck will be at CES in the Mobility in Harmony Consortium Booth in the West Hall Booth 5274.

07:34 EST CI Financial reports November AUM $384.9B, up 16.5% y/y

07:31 EST BridgeBio initiates Phase 3 trial CALIBRATE study of encaleret - BridgeBio Pharma announced the initiation of its multicenter, international, pivotal Phase 3 randomized trial of encaleret in patients with autosomal dominant hypocalcemia type 1, ADH1, CALIBRATE. The design of the CALIBRATE study incorporates feedback from global regulatory authorities and patients, with a primary composite endpoint of blood and urine calcium concentrations within normal ranges in participants treated with encaleret compared to standard of care, SoC. SoC for ADH1 consists of extra-dietary supplementation with calcium and/or active vitamin D analogs. While SoC may address acute symptoms related to hypocalcemia, it may exacerbate high urine calcium levels, which can cause renal complications. Secondary endpoints will evaluate other measures of mineral homeostasis, quality of life, and kidney function. "We are excited to have reached this important milestone in the development of encaleret," said Mary Scott Roberts, executive director of clinical development at BridgeBio and clinical lead of the encaleret program. "The pivotal CALIBRATE study will evaluate the potential for encaleret to provide a meaningful benefit to patients and families living with ADH1. If successful, this study could lead to an approval of encaleret for the treatment of ADH1, a disease with significant unmet medical need and no interventions specifically indicated for its treatment."

07:13 EST Elite Pharmaceuticals files ANDA with FDA to market dopamine agonist - Elite Pharmaceuticals announced that it filed an Abbreviated New Drug Application with the US Food and Drug Administration for an undisclosed extended-release generic drug product in a class of medications called dopamine agonists. For the twelve months ending August 31, 2022, the dopamine agonist had total US sales of approximately $12 million, according to IQVIA data.

07:11 EST Xos publishes 2022 year-end video - Xos published its 2022 year-end video. The video celebrates accomplishments made starting at the beginning of Q4 2021 through the end of Q3 2022. Particular highlights include an increase in truck deliveries, the unveiling of new vehicles MDXT and HDXT, the Xosphere fleet management platform, and Xos DC Fast Chargers, and more.

07:09 EST Marimaca Copper qualified to trade on the OTCQX - OTC Markets announced Marimaca Copper has qualified to trade on the OTCQX Best Market. Marimaca Copper Corp. upgraded to OTCQX from the Pink market. Marimaca Copper Corp. begins trading today on OTCQX under the symbol "MARIF." "We are very pleased to complete our upgrade to OTCQX. Marimaca is rapidly progressing toward development and we look forward to engaging with a broader range of investors in the US market at this exciting time for the Company" - Hayden Locke, President and CEO.

07:08 EST BioCardia CEO says coming year offers potential for catalysts - BioCardia issued a letter to shareholders, which read in part, "BioCardia is now advancing four novel cell therapies, with three focused on heart disease, a leading cause of death and reduced quality of life globally. The Phase III trial of our lead therapy - CardiAMP autologous cell therapy for ischemic heart failure - continues to enroll in the U.S. and Canada, and data published to-date is showing improved functional capacity and quality of life in treated patients. Most encouraging is the combined mortality rate across the Phase I, II and III trial data available, which is less than3% per year, exceptional in a landscape where leading pharmaceutical solutions are showing mortality that is 3x higher. The FDA has supported this promise by granting Breakthrough Device Designation to CardiAMP cell therapy in this indication. We have embarked on a Phase III trial of CardiAMP autologous cell therapy in a second indication addressing chronic myocardial ischemia, and this year received IND approval from the FDA to study two allogeneic product candidates, both leveraging Neurokinin-1 receptor positive allogeneic mesenchymal stem cells - BCDA-03 for ischemic heart failure and BCDA-04 for acute respiratory distress syndrome. The NK1R+ cells are particularly interesting as NK1 is the primary receptor for Substance P, an important neuropeptide mediator of inflammation which plays a central role in both heart failure and regenerative processes following myocardial injury...An adaptive SAP design is well underway using a Bayesian approach and we anticipate looking at the operating characteristics for the design in early January with an FDA "sprint discussion" afforded under the breakthrough designation to follow. In parallel, we anticipate all data that contributes to the primary efficacy endpoint in the study submission to have been monitored by our very capable clinical research staff verifying all clinical data required for interpretation. While we expect this will all be in place for a DSMB review in Q2 2023, there are also no guarantees we will be able to implement such a plan or that implementation of such a plan will result in an early end to the clinical trial for efficacy at of the future DSMB review...We expect 2022 work on the regulatory and reimbursement fronts, activation of the trial in Canada, and enhanced patient education efforts to have a positive impact on enrollment in 2023. We also intend to publish and present new data from the CardiAMP HF Trial designed to further influence referrals to the trial among heart failure specialists. To this point, we have seen some reluctance among these specialists concerned about losing control of patients to physicians in the trial, expressing the aforementioned skepticism about cell therapy, and feeling that the new heart failure drugs available will adequately serve their patients...In 2023, we intend to submit for regulatory approval of CardiAMP cell therapy in Japan. We plan to prioritize pursuit of a petition for a special designation as a highly needed medical therapy from a leading Japanese clinical society to the Ministry of Health Labor and Welfare to support enhanced reimbursement and regulatory approval. Should the special designation not be granted, we will pursue regulatory approval through a traditional pathway...On the heels of our 2022 deal with BlueRock Therapeutics to provide our Helix delivery system for their therapeutic development efforts, we are discussing partnerships with leading biopharmaceutical firms where BioCardia may benefit from licensing fees and milestones during development, as well as a percentage of sales once those therapies enabled by our delivery products are commercial. In parallel to our efforts to achieve regulatory approval in Japan, we are in discussions with potential distribution partners in Japan which, if finalized, could lead to commercial revenue...Now that we have both INDs approved by FDA and clinical-grade cells manufactured in our facility, the next milestones for our allogeneic NK1R+ mesenchymal stem cell indications of heart failure and acute respiratory distress involve treating the first patients in these studies. For the acute respiratory distress indication, we are actively completing the clinical site start-up phase of aligning on patient informed consent, clinical study agreement, and budget which we anticipate completing for at least one site in the weeks ahead. Even as we make progress on these new programs, our priority is our BCDA-01 CardiAMP cell therapy program based on the positive data we are seeing and the Breakthrough designation that has potential to accelerate our regulatory and commercial efforts."

07:07 EST Pluri CEO issues letter to shareholders on progress in 2022 - Pluri issued the following update to shareholders from CEO and President Yaky Yanay and announced that as planned the Company's joint venture with Tnuva Group has successfully achieved proof of concept in its development of cultivated meat based on Pluri's proprietary 3D cell-based technology platform. "As we look toward a promising year ahead, I am proud to reflect on all that Pluri has achieved throughout 2022. This year, we launched a new Company strategy leveraging on our 3D cell-based technology platform to improve human wellbeing, increase sustainability, and advance solutions to humanity's greatest challenges... We marked this evolution of our Company by adopting a new name, Pluri, representative of the many ways that our cell-based solutions can tackle some of our planet's greatest challenges... Earlier this year, we formed a joint venture with Tnuva Group, Israel's largest food producer, to develop cultivated meat products... Today, I am proud to report that our joint venture has successfully completed proof of concept in its development of cultivated meat based on our cell-based technology platform. While we were setting an aggressive development plan for the R&D teams it was important for me to see that we were able to meet each and every milestone we set, which indeed happened - and most of the time ahead of schedule...Pluri launched a second technology collaboration in September, this time with one of the leading European manufacturers of active pharmaceutical ingredients. The market for biologic medications is expected to nearly double by 2030 to an estimated $720 billion, and Pluri anticipates to continue to generate revenues from this collaboration in the coming months... Earlier this year, we announced positive final results from a Phase I hematology study of the safety and potential efficacy of injecting Pluri's PLX-R18 cells in patients recovering from hematopoietic cell transplantation... In addition, Pluri and our partners in PROTO, an international collaboration led by Charite, Berlin Institute of Health Center for Regenerative Therapies, studying the treatment of mild-to-moderate knee osteoarthritis using Pluri's PLX-PAD cells, were awarded a EUR 7.5 million non-dilutive grant from the European Union's Horizon Europe program...Pluri remains well positioned to capitalize on these achievements and expand on our progress in 2023, following actions earlier this year to reduce the Company's cash burn by an estimated 30%... I deeply believe in the promise of Pluri and the new path forward that we began forging this year. We believe our new strategy has yielded significant achievements in recent months that set us up for further success in 2023. With that in mind, I decided to forego $375,000 of my cash salary over the next 12 months and instead receive equity grants."

07:05 EST Electra launches battery materials recycling demonstration plant in Ontario - Electra Battery Materials announced the launch of a demonstration plant designed to recover and recycle high-value elements found in lithium-ion batteries, including nickel, cobalt, lithium, copper, and graphite at its refinery complex north of Toronto. "The launch of our black mass recycling demonstration plant caps a year filled with a number of significant achievements for Electra," said Trent Mell, Electra's CEO. "With the outlook for electric vehicle adoption in North America becoming increasingly bullish as a result of the recent passage of the U.S. Inflation Reduction Act and the considerable investments made by automotive companies to electrify their fleet, the need for a domestic supply of battery-grade materials supply whether through primary refining or recycling processes becomes critical."

07:03 EST Bausch Health' acne lotion included in drug plans of four Canadian provinces - Bausch Health's new topical prescription treatment for acne vulgaris, Arazlo, is now available to patients through the provincial public drug plans of Quebec, Ontario, Alberta and Saskatchewan, as well as the federal government's Non-Insured Health Benefits drug plan, which serves Canada's First Nations and Inuit populations. Arazlo is the first tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older. The listings by the four public drug plans are the first for Arazlo in Canada, with others expected to follow as a result of the successful conclusion of listing negotiations with the pan-Canadian Pharmaceutical Alliance.

07:02 EST Quanta Services selected by Xcel Energy for Colorado's Power Pathway project - Quanta Services announced that it has been selected by Xcel Energy as its prime constructor to manage all construction activities for the Colorado's Power Pathway high-voltage electric transmission project in Colorado. Quanta's scope of work on the project consists of the construction of approximately 610 miles of 345 kV transmission infrastructure, consisting of up to six segments and spanning more than a dozen counties, primarily in eastern Colorado, and includes the installation of four new substations and the expansion of four existing substations. The project is designed to increase the reliability of the state's power grid and enable future renewable energy development in Colorado, including approximately 5,500 megawatts of new wind, solar and other resources that Xcel Energy plans to add through 2030.

06:54 EST CarMax falls 7% to $55.11 after Q3 results miss estimates

06:52 EST CarMax reports Q3 total retail used units sold decreased 20.8% - Total retail used units sold decreased 20.8%, while used unit sales in comparable stores were down 22.4%; strength in margin management delivered solid gross profit per retail used unit of $2,237, in line with the prior year third quarter. Total wholesale units sold decreased 36.7%; despite a decrease of $165 per unit from the record prior year third quarter, wholesale gross profit per unit remained strong at $966. Both volume and margins were impacted by steep market depreciation as well as retail selectivity. Bought 238,000 vehicles from consumers and dealers, down 39.8% versus last year's record third quarter, due to steep market depreciation and our response to deliberately slow buys.

06:49 EST Merck and Kelun Biotech sign license and collaboration agreement in cancer - Merck and Kelun-Biotech, a holding subsidiary of Sichuan Kelun Pharmaceutical, a clinical-stage biotech company focused on biologic and small molecule discovery and development, have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates - ADC - for the treatment of cancer. Under the agreement, Kelun-Biotech has granted Merck exclusive global licenses to research, develop, manufacture and commercialize multiple investigational preclinical ADC therapies and exclusive options to obtain additional licenses to ADC candidates. Kelun-Biotech retains the right to research, develop, manufacture and commercialize certain licensed and option ADCs for mainland China, Hong Kong and Macau. Kelun-Biotech will receive an upfront payment of $175M from Merck. Kelun-Biotech is also eligible to receive future development, regulatory and sales milestone payments totaling up to $9.3B. Merck also intends to make an equity investment in Kelun-Biotech. The transaction is subject to customary closing conditions and shareholder approvals.

06:32 EST Affimed's Phase 1 study of AML candidate approved in France - Affimed announced that the French National Agency for the Safety of Medicines and Health Products has authorized a Clinical Trial Application for the phase 1 study of AFM28 in relapsed/refractory acute myeloid leukemia, or AML. CTA applications for AFM28-101 in other European jurisdictions are ongoing, and additional applications are planned for submission early in 2023. Additionally, Affimed plans to investigate AFM28 in combination with allogenic natural killer cell therapy.

06:12 EST Airbus' Pleiades Neo 5, 6 satellites lost after Arianespace's rocket fails - Arianespace announced on December 20 the failure of Flight VV22 carrying Pleiades Neo 5 & 6 satellites. These satellites were developed by Airbus and would have completed the Pleiades Neo fleet. The Vega C launch vehicle lifted off as scheduled on December 20, 2022 at 10:47 pm, local time in French Guiana. The lift-off, the mission and the separation of the first stage, P120C, were nominal. Following the nominal ignition of the second stage's, Zefiro 40, engine around 144 seconds after lift-off, a decrease in the pressure was observed leading to the premature end of the mission. Under standard procedure, the order of destruction of the launcher was given by CNES, the launch safety authority; no damage to persons or properties occurred. Arianespace and the European Space Agency, ESA, immediately decided to appoint an independent inquiry commission. This commission is tasked with analyzing the reasons for the failure and defining the measures fulfilling all requisite safety and reliability conditions to allow the resumption of Vega C flights.

06:04 EST Rocket Pharmaceuticals provides update on registration path for RP-A501 - Rocket Pharmaceuticals provided an update from the company's end-of-Phase 1 meeting with the FDA regarding RP-A501, the company's investigational adeno-associated virus-based gene therapy for Danon Disease. During the meeting, Rocket reviewed the positive Phase 1 dataset with the FDA and proposed a study design and endpoints for ongoing clinical development of the investigational gene therapy. Based on the ongoing FDA discussion, Rocket is to pursue a biomarker-based composite endpoint for a single arm, open-label pivotal trial with a natural history comparator Initiation of initial component of global study is anticipated in 1H'23. Results from the ongoing Phase 1 Danon Disease trial show that RP-A501 was generally well tolerated with evidence of durable treatment activity and improvement of Danon Disease for both pediatric patients with up to nine months of follow-up and four adult patients with up to 36 months of follow-up.

06:02 EST Eli Lilly, ProQR Therapeutics to expand RNA editing collaboration - Eli Lilly and Company (LLY) and ProQR Therapeutics (PRQR), announced the expansion of their licensing and collaboration agreement focused on the discovery, development and commercialization of new genetic medicines. The collaboration, originally announced in September 2021, applied ProQR's proprietary Axiomer RNA editing platform to target disorders of the liver and nervous system. Through the course of work to date, advances in the platform have significantly increased editing efficiency and refined biodistribution in both the liver and nervous system, opening up new potential applications to not only correct known mutations, but also introduce protective variants in specific transcripts. Through this expanded collaboration, Lilly and ProQR will explore further applications of the Axiomer platform to unlock new innovative treatments for people living with diseases with high unmet medical need. Under the terms of the expanded agreement, Lilly will gain access to additional targets in the central nervous system and peripheral nervous system with ProQR's Axiomer platform. ProQR will receive $75M consisting of an upfront payment, as well as an equity investment. Lilly will have the ability to exercise an option to further expand the partnership for a consideration of $50M. In addition, Lilly can elect to provide ProQR with access to the company's proprietary delivery technology for its wholly owned pipeline. Based on its original September 2021 agreement and the expanded agreement announced today with Lilly, in total, ProQR is eligible to receive up to approximately $3.75B in research, development and commercialization milestones, as well as tiered royalties of up to mid-single digit percentage on product sales.

05:57 EST Angion Biomedica receives noncompliance notification from Nasdaq - Angion Biomedica announced that on December 15, it received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying Angion that for the last 30 consecutive business days the bid price of Angion's common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450.

05:50 EST OKYO Pharma receives FDA clearance of OK-101 IND - OKYO Pharma announced that it has received clearance of its investigational new drug, or IND, application from the FDA to initiate a Phase 2, first-in-human, clinical study of OK-101 for the treatment of DED. The FDA previously concurred with OKYO's plans for designating primary and secondary efficacy endpoints covering both a sign and a symptom of DED in the clinical study protocol.

05:48 EST Ever-Glory to voluntarily delist from Nasdaq - Ever-Glory announced that after stockholders' approval in the meeting on December 18, the company has applied to voluntarily delist its common stock from the Nasdaq Global Market. December 23 will be the last trading day of the company's common stock on Nasdaq Global Market.

05:44 EST Elbit Systems awarded $36M contract to supply four F-16 Full Mission Simulators - Elbit Systems announced that it was awarded a contract valued at approximately $36M to supply four F-16 Full Mission Simulators, or FMS, to the Polish Air Force, or PLAF. The contract will be performed over a 28-month period. The simulation technology at the core of the Mission Training Center enables higher quality training and improves mission readiness. Featuring a 360-degree display system, the interconnected simulators provide a high fidelity, full mission training experience. By providing an immersive real flight experience with no safety limitations, Elbit Systems' training solution will provide PLAF F-16 pilots with a range of skills from basic familiarity with the aircraft to advanced combat flight competencies in complex operational arenas. Elbit Systems' training and simulation technologies can also provide the future simulation infrastructure of the PLAF, enabling connectivity to additional training devices for Live, Virtual and Constructive training.

05:37 EST Partner executes fiber optic line agreement with Israel Telecommunication Corp. - Partner Communications announced that on December 21, an agreement was executed between the company and Bezeq - the Israel Telecommunication Corp., regarding the purchase of an indefeasible and irrevocable right of use for 15 years of 120 thousand non-specific fiber optic infrastructure lines in buildings connected to Bezeq's fiber-optic infrastructure. In accordance with the agreement, the right to use the Fiber Optic Lines will be granted in five equal annual installments, with the first installment beginning on January 1, 2023. The total consideration that the company will pay Bezeq for the right of use in accordance with the agreement is approximately NIS 574M plus VAT for the First Agreement Period, that will be divided into five equal payments, that will be paid at the beginning of each calendar year of the years 2023 until 2027, plus half of the linkage differences, and all in accordance with the terms set forth in the agreement. The company has the option to divide each Installment Amount over a period of five years, with interest to be added at a rate equal to Bezeq's NIS bond yield at the relevant average duration that will be known at the date of right of use of the Fiber Optic Lines for that installment. The company will also pay annual maintenance fees at a rate of 4% of the consideration, plus linkage differences, in accordance with the terms set forth in the agreement, for all of the Fiber Optic Lines for which the company was granted a right of use until that year. The company has been provided with an option to purchase the right to use 48 thousand additional Fiber Optic Lines, under the same terms, during the first agreement period, as well as an option to extend the period of use for two additional five-year periods each, beyond the first agreement period, at a lower cost per fiber optic line than during the first agreement period.

05:15 EST CareDx says publication of ISHLT guidelines support cardiothoracic portfolio - CareDx announced the publication of new guidelines by the International Society for Heart and Lung Transplantation, or ISHLT, supporting the use of CareDx's non-invasive molecular surveillance portfolio. The new ISHLT guidelines support the use of CareDx's cardiothoracic portfolio, AlloMap Heart, AlloSure Heart, and HeartCare. Specifically, the guidelines: support the earlier use of AlloMap Heart starting at two months to five years post-transplant versus starting at six months based on strength of clinical studies; support AlloMap gene-expression profiling, or GEP, and donor-derived cell-free DNA, or dd-cfDNA, for routine post-transplant monitoring, which is new in the current guidelines and reflects increased adoption of non-invasive molecular testing in clinical practice. This includes dd-cfDNA which is new in the current guidelines. Support remote use of GEP and dd-cfDNA heart transplant surveillance, as in HeartCare, as it may be used to reduce the need for biopsies and hospital visits, which is new in the current guidelines, and as evidenced during the recent COVID pandemic.

05:10 EST M2 Capital updates offer to acquire Superior Industries for $5.85 per share - M2 Capital provides an update on its tender. M2 Capital submitted an offer letter to Superior, earlier this month. Once Superior answers M2 Capital's Letter - M2 Capital will file a Schedule TO with the U.S. Securities Exchange Commission. The offer is subject to customary and other terms and conditions. The letter read, "This letter is an offer (the "Offer") from M2 CAPITAL PARTNERS (UK) LIMITED (the "M2 Capital" or "M2C") to acquire 100% of the outstanding shares of SUPERIOR INDUSTRIES INTERNATIONAL, INC. ("Superior" or the "Company") (NYSE:SUP). The Offer is for US$5,85 per Superior share. M2 Capital is an ANGLO-CANADIAN private equity/investment firm focused on value creation. M2 Capital is focused on four types of efficiencies: (1) Managerial - we augment the management team, as necessary; (2) Operational - we bring in top consultants to optimize assets; (3) Technical- we invest in the newest / best-in-class technologies; and, (4) Capital - we optimize the capital base to best fit the company's needs. M2 Capital's Offer includes: (1) a guarantee to maintain all employees for a period of 2 ("two") years - from the date of acquisition of Superior, and, (2) a 6,5% (a "six and a half percent") increase in salaries for all employees - from the date of acquisition of Superior. The aggregate equity purchase price, assuming all outstanding shares are tendered, is anticipated to be close to US$160 million. The transaction will be FUNDED by CASH. The Offer is subject to customary and other terms and conditions. M2 Capital will shortly file, with the US Securities Exchange Commission ("SEC"), a Schedule TO.